• Molecular NameTripelennamine
  • SynonymNA
  • Weight255.365
  • Drugbank_IDDB00792
  • ACS_NO91-81-6
  • Show 2D model
  • LogP (experiment)2.7
  • LogP (predicted, AB/LogP v2.0)3.12
  • pka3.9, 9.0 (25°)
  • LogD (pH=7, predicted)1.33
  • Solubility (experiment)0.588 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.38
  • LogSw (predicted, AB/LogsW2.0)0.76
  • Sw (mg/ml) (predicted, ACD/Labs)0.61
  • No.of HBond Donors0
  • No.of HBond Acceptors3
  • No.of Rotatable Bonds6
  • TPSA19.37
  • StatusFDA approved
  • AdministrationOral, Intravenous
  • PharmacologyA psychoactive drug and member of the pyridine and ethylenediamine chemical classes that is used as an antipruritic and first-generation antihistamine.
  • Absorption_valueN/A
  • Absorption (description)Well absorbed in the digestive tract.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic hydroxylation and glucuronidation
  • Half lifeN/A
  • ExcretionRenal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySymptoms of overdose include clumsiness or unsteadiness, convulsions, drowsiness, dryness of mouth, nose, or throat, feeling faint, flushing or redness of face, hallucinations, muscle spasms (especially of neck and back), restlessness, shortness of breath or troubled breathing, shuffling walk, tic-like movements of head and face, trembling and shaking of hands and trouble in sleeping.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A